SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Upgraded by Zacks Research

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on SABS. Chardan Capital upped their target price on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Rodman & Renshaw restated a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday. Wall Street Zen cut SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Finally, HC Wainwright upped their price target on SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABS opened at $3.62 on Monday. The firm has a fifty day simple moving average of $3.86 and a 200 day simple moving average of $3.81. SAB Biotherapeutics has a twelve month low of $1.60 and a twelve month high of $6.60. The company has a quick ratio of 9.46, a current ratio of 9.46 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $184.44 million, a PE ratio of -1.56 and a beta of 0.55.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, sell-side analysts forecast that SAB Biotherapeutics will post -1.1 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. purchased a new position in SAB Biotherapeutics during the first quarter valued at approximately $29,000. ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics in the 3rd quarter worth approximately $30,000. Dimensional Fund Advisors LP purchased a new stake in SAB Biotherapeutics in the 3rd quarter worth approximately $32,000. State of Wyoming bought a new position in SAB Biotherapeutics in the 4th quarter valued at $34,000. Finally, Virtu Financial LLC purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at $40,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.